SMA screening with Horizon^TM

With new treatments for spinal muscular atrophy (SMA), screening isn’t just knowledge. Carrier screening means informed decisions and the opportunity for earlier, more effective, treatment; it means the chance to change the course of a child’s life.

Learn about SMA and the need for screening through Lola’s story

“It went from, ‘I’m going to coach her soccer or softball team’… to ‘I’m going to coach her how to roll around in a wheelchair and maybe one day she’ll walk.'”

Brady Camp

Father of Lola (born with SMA)

Find out how knowing their carrier status led to different outcomes in their two kids with SMA

Alyssa and Michiel learned that they were carriers of SMA after their daughter, Annabelle, was diagnosed at 2 months of age. When they became pregnant again with Annabelle’s younger brother Jude, knowing their SMA carrier status allowed them to plan for earlier diagnosis and treatment. Jude received his first treatment at 9 days old.

Read story

View Our Webinar: Enabling Better Outcomes Through SMA Carrier Screening

With the availability of SMA gene therapies, carrier screening can lead to earlier treatment and better outcomes. Learn how you can make a difference by offering carrier screening to your patients.

Hear from Alecia, whose daughter Lola was diagnosed with SMA at 5 1⁄2 months of age, and Dr. Barry Byrne, a pediatric cardiologist and gene therapy expert at the University of Florida. In the webinar, they discuss how carrier screening can impact the SMA treatment timeline and change the course of a child’s life.

Alecia Camp

Mother of Lola who was diagnosed with SMA at 5 months of age
Barry Byrne, MD

Pediatric cardiologist specializing in gene therapy at the University of Florida

Learn More About Horizon

All carrier screening is not equal, and choosing the right test for your patients is critical. Traditional SMA screens¹ miss ~60% of patients Horizon identifies as at-risk SMA carriers.^2,3 Learn how Horizon leverages advanced technology and unmatched support to help you and your patients.

Learn more

References

¹Prior and Professional Practice Guidelines Committee. Genet Med. 2008;10:840–842.

²McAndrew et al. Am J Hum Genet. 1997;60(6):1411-1422.

³Westemeyer et al. Genet Med. 2020;22(8):1320-28.